72 completed. 72 Phase 2, 13 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 72 | Completed 72 |
| Phase 1 | 13 | Completed 13 |
| Phase 3 | 6 | Completed 6 |
Follow Agranulocytosis: new trials by email Literature Review of Agranulocytosis trials Research Report on Agranulocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Tranexamic Acid and Calcium Dobesilate for Bleeding of Endometrial Origin Tranexamic Acid, Calcium dobesilate (Doxium) - Heavy. Mentrual Bleeding, Abormal utèrine Bleeding | Phase 2 / Phase 3 | Completed | District Headquarters Teaching Hospital Sahiwal | 100 | 2022-01-01 | 2024-11-27 |
| A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders Mavorixafor - Neutropenia | Phase 1 / Phase 2 | Completed | X4 Pharmaceuticals | 32 | 2021-10-16 | 2025-08-06 |
| Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy Day 7 regimen, Day 3 regimen - Breast Cancer | Phase 2 | Completed | The First Affiliated Hospital with Nanjing Medical University | 160 | 2021-07-13 | 2023-02-23 |
| Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial Anakinra, Placebos - Multiple Myeloma | Phase 2 | Completed | Radboud University Medical Center | 88 | 2019-11-04 | 2024-11-18 |
| Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer PEG-rhG-CSF, rhG-CSF - Cervical Cancer | Phase 2 | Completed | Chongqing University Cancer Hospital | 60 | 2018-08-01 | 2023-09-06 |
| Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer EC-18 - Febrile Neutropenia | Phase 1 / Phase 2 | Completed | Enzychem Lifesciences Corporation | 28 | 2017-10-30 | 2026-11-04 |
| Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients rHSA-GCSF 2.4mg, GCSF - Chemotherapy-induced Neutropenia | Phase 2 | Completed | Tianjin SinoBiotech Ltd. | 80 | 2017-10-19 | 2019-09-13 |
| Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT Anakinra - Multiple Myeloma | Phase 2 | Completed | Radboud University Medical Center | 9 | 2017-08-21 | 2024-11-18 |
| Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia Isavuconazole - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Completed | M.D. Anderson Cancer Center | 65 | 2017-03-28 | 2021-10-26 |
| Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis Lozanoc - Neutropenia | Phase 2 | Completed | Mayne Pharma International Pty Ltd | 20 | 2016-07-01 | 2018-10-26 |
| Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis CBLB612, Placebo - Breast Cancer | Phase 2 | Completed | BioLab 612 LLC | 23 | 2015-12-01 | 2016-07-20 |
| A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement tbo-filgrastim - Neutropenia | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 50 | 2015-05-12 | 2021-12-10 |
| Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer Carboplatin/paclitaxel - Advanced Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Completed | Cairo University | 49 | 2015-01-01 | 2023-07-27 |
| Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia CLT-008, G-CSF - Acute Myeloid Leukemia, Neutropenia | Phase 2 | Completed | Cellerant Therapeutics | 163 | 2014-12-01 | 2018-09-27 |
| Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Plerixafor, G-CSF - Myelokathexis, Infections | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2014-10-14 | 2026-06-26 |
| A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy. F-627, Filgrastim - Neutropenia | Phase 2 | Completed | EVIVE Biotechnology | 138 | 2014-07-03 | 2018-02-23 |
| A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy F-627 240 μg/kg, F-627 320 μg/kg - Neutropenia | Phase 1 / Phase 2 | Completed | EVIVE Biotechnology | 15 | 2014-02-25 | 2019-11-21 |
| Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle - Non Small Cell Lung Cancer, Breast Cancer | Phase 2 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 80 | 2013-12-01 | 2018-07-17 |
| LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy Lifemel - Neutropenia, Adverse Event | Phase 2 | Completed | VitalMel | 39 | 2013-11-11 | 2020-09-24 |
| Study of Danggui Buxue Decoction in Preventing Neutropenia DBD, Epirubicin, Cyclophosphamide - Grade 3/4 Neutropenia, Febrile Neutropenia | Phase 2 | Completed | Shanghai Jiao Tong University School of Medicine | 50 | 2013-10-01 | 2015-12-30 |
Showing 20 of 72. Sign in to see all of them.
Neutropenia (65) · Breast Neoplasms (12) · Thrombocytopenia (12) · Febrile Neutropenia (11) · Anemia (8) · Leukemia (8) · Infections (7) · Anemia, Aplastic (6) · Autoimmune Diseases (5) · Fever (5) · Leukemia, Myeloid, Acute (4) · Lymphoma (4) · Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Cytopenia (3)
Hemic and Lymphatic Diseases (72) · Leukocyte Disorders (72) · Leukopenia (70) · Cytopenia (69) · Hematologic Diseases (69) · Neoplasms (35) · Immune System Diseases (23) · Neoplasms by Site (21) · Neoplasms by Histologic Type (20) · Pathological Conditions, Signs and Symptoms (16) · Skin and Connective Tissue Diseases (16) · Blood Platelet Disorders (14) · Lymphoproliferative Disorders (14) · Skin Diseases (14)
Filgrastim (14) · pegfilgrastim (13) · Cyclophosphamide (8) · Cyclosporine (4) · Cytarabine (4) · Docetaxel (4) · Etoposide (4) · Alemtuzumab (3) · Doxorubicin (3) · pegylated granulocyte colony-stimulating factor (3) · Anidulafungin (2) · Cisplatin (2) · Daunorubicin (2) · Fluorouracil (2) · Granulocyte Colony-Stimulating Factor (2)
Amgen (8) · National Heart, Lung, and Blood Institute (NHLBI) (8) · EVIVE Biotechnology (3) · National Cancer Institute (NCI) (3) · Alliance for Clinical Trials in Oncology (2) · Memorial Sloan Kettering Cancer Center (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Pfizer (2) · Radboud University Medical Center (2) · AviGenics (1) · BioLab 612 LLC (1) · Biocad (1) · Cairo University (1) · Cellerant Therapeutics (1) · Centre Francois Baclesse (1)
United States (34) · China (9) · Netherlands (4) · Australia (3) · South Korea (3) · Bulgaria (2) · Canada (2) · France (2) · Georgia (2) · Hungary (2) · Poland (2) · Russia (2) · Switzerland (2) · Botswana (1) · Croatia (1)
Danielle M Townsley, M.D. (4) · Cynthia E Dunbar, M.D. (2) · David H McDermott, M.D. (2) · Nicole Blijlevens, MD PhD (2) · Thomas J. Walsh, MD (2) · A Vulto, PhD (1) · Aleksei G. Manikhas, MD PhD (1) · Andrea Pietro Sponghini (1) · Antonius Miller, MD (1) · Bart Biemond, MD PhD (1) · Bart JA Rijnders, MD, PhD (1) · Binghe XU, MD (1) · Chang-Hee Lee, M.D., Ph.D. (1)
PMID 29958797, PMID 34724566, PMID 16382125, PMID 17170128, PMID 18156492, PMID 18616811, PMID 18827613, PMID 19208097, PMID 20045791, PMID 20431381, PMID 21890643, PMID 22067384, PMID 23909727, PMID 24523241, PMID 24723677, PMID 25185712, PMID 26504182, PMID 26765645, PMID 27658437, PMID 28339500, PMID 28395844, PMID 29119726, PMID 29140155, PMID 29524595, PMID 29573207, PMID 29674506, PMID 30992268, PMID 31022078, PMID 32236406, PMID 32330244, PMID 33225965, PMID 33384016, PMID 33789616, PMID 34078317, PMID 34156898, PMID 34858760, PMID 35546555, PMID 37561579, PMID 37641932, PMID 38194162, PMID 39533204, PMID 40330596, PMID 41066031, PMID 42606118, PMID 9771955
2014 (1), P30CA036727 (1), R01HD061265 (1), U10CA031946 (1), U10CA032102 (1)